Praxis Precision Medicines remains a Hold as valuation now reflects high expectations for ulixacaltamide and its epilepsy ...

This study offers important insight into the pathogenic basis of intragenic frameshift deletions in the carboxy-terminal domain of MECP2, which account for some Rett syndrome cases, yet similar ...

A powerful earthquake struck the rugged highlands of Papua New Guinea on December 22, 2025. The tremor measured 6.5 in ...

An investigation into the 28 March 2025 collapse of Bangkok's SAO tower, exploring the human cost, flawed construction, and ...

Scientists are increasingly convinced that what happens in the mouth does not stay in the mouth. A growing body of research ...

Based Detection, Linguistic Biomarkers, Machine Learning, Explainable AI, Cognitive Decline Monitoring Share and Cite: de Filippis, R. and Al Foysal, A. (2025) Early Alzheimer’s Disease Detection from ...

Praxis Precision Medicines has won Food and Drug Administration breakthrough-therapy designation for its ulixacaltamide drug candidate for the treatment of patients with essential tremor.

Praxis Precision Medicines Inc (NASDAQ: PRAX) stock rose after FDA granted BTD for ulixacaltamide to treat essential tremor.

In December 2025, Praxis announced the successful completion of its pre-NDA meeting with the FDA, including the receipt of written feedback and an in-person meeting. The Company has aligned with the ...

Medicare is launching a new pilot program that will require prior approval for 17 health services using artificial ...

In 2026 a decade will have passed since the Brexit referendum (yes, that threw me too). Fittingly, then, the Europe question ...

When I was about 6 years old in the early ‘40s, my 16-year-old brother was sent to a sanitarium for tuberculosis patients. He ...